| Literature DB >> 11470822 |
D Kornitzer1, R Sharf, T Kleinberger.
Abstract
Adenovirus early region 4 open reading frame 4 (E4orf4) protein has been reported to induce p53-independent, protein phosphatase 2A (PP2A)-dependent apoptosis in transformed mammalian cells. In this report, we show that E4orf4 induces an irreversible growth arrest in Saccharomyces cerevisiae at the G2/M phase of the cell cycle. Growth inhibition requires the presence of yeast PP2A-Cdc55, and is accompanied by accumulation of reactive oxygen species. E4orf4 expression is synthetically lethal with mutants defective in mitosis, including Cdc28/Cdk1 and anaphase-promoting complex/cyclosome (APC/C) mutants. Although APC/C activity is inhibited in the presence of E4orf4, Cdc28/Cdk1 is activated and partially counteracts the E4orf4-induced cell cycle arrest. The E4orf4-PP2A complex physically interacts with the APC/C, suggesting that E4orf4 functions by directly targeting PP2A to the APC/C, thereby leading to its inactivation. Finally, we show that E4orf4 can induce G2/M arrest in mammalian cells before apoptosis, indicating that E4orf4-induced events in yeast and mammalian cells are highly conserved.Entities:
Mesh:
Substances:
Year: 2001 PMID: 11470822 PMCID: PMC2150760 DOI: 10.1083/jcb.200104104
Source DB: PubMed Journal: J Cell Biol ISSN: 0021-9525 Impact factor: 10.539
Figure 1.E4orf4 inhibits growth in W303 cells (A) or mutant cells (B–D) transformed with the indicated plasmids were plated on galactose (B–D) or on glucose versus galactose (A) and allowed to grow for 2 d. (E) Proteins were prepared from the yeast cells used in A–D, and E4orf4 levels were analyzed by Western blot. A3, the E4orf4 A3 mutant.
Growth of various yeast mutants in the presence of E4orf4
| Yeast strain | Plasmid | |
|---|---|---|
| p426-GalL-E4orf4 | pDAD-E4orf4 | |
| W303 | − | ++ |
| cdc55 | +++ | ND |
|
| − | − |
| rts1 | − | ND |
| cdc55 | +++ | ND |
| tpd3 | +++ | ND |
| pph21 | − | ND |
| pph22 | − | ND |
| pph3 | − | ND |
| sit4-36 | - | ND |
| ppg1 | − | ND |
| cdc28-4 | ND | ± |
| cdc28-1N | ND | − |
| clb1 | ND | − |
| mih1 | ND | − |
| swe1 | − | ++ |
|
| ND | − |
| swe1 | − | ++ |
| CDC28F19 | − | ++ |
| cdc34-2 | ND | ++ |
| cdc53-1 | ND | ++ |
| cdc15-2 | ND | ++ |
| sic1 | ND | ++ |
| cdc20-1 | ND | − |
| cdh1 | ND | − |
| pds1 | − | ++ |
| cdc16-1 | ND | − |
| CDC16-6A CDC23-A CDC27-5A | − | ND |
| mad1 | − | ND |
| mad2 | − | ND |
| mad3 | − | ND |
| bub1 | − | ++ |
| bub2 | − | ND |
Figure 2.E4orf4-induced growth arrest is irreversible and occurs both in wild-type and ▪, cells containing vector plasmid; •, cells expressing E4orf4. (A) Cells were transferred from raffinose to galactose at time 0. Aliquots were collected at various time points after induction, and cells were counted microscopically. (B) The experiment was done as in A, but at 9 and 24 h after induction cells were diluted to 3 × 106/ml in medium containing galactose and allowed to continue growing. (C) At the time points shown in A, 1,000 cells were plated on glucose plates. Colonies were counted after 2 d, and the number of colonies at time 0 was defined as 100%. (D) A similar experiment as described in C was performed, except a doxycycline-regulatable promoter was used, E4orf4 expression was induced by removal of doxycycline at time 0, and rho-0 cells (□ and ○) were compared with wild-type cells (▪ and •). Every experiment shown is one of a series of three that yielded similar results.
Figure 3.ROS accumulate in E4orf4-expressing cells. Cells carrying pGalL-E4orf4 or the vector plasmid were grown for 6 h in galactose medium and were then stained for 10 min with 1 μg/ml dihydroethidium (DHE). Fluorescence was visualized through a rhodamine filter on a Zeiss Axioscop, at a magnification of 600×. The proportion of dihydroxyethidium-stained cells was measured by FACS® analysis (right).
Figure 4.E4orf4-expressing cells accumulate in different stages of mitosis. (A) Cells carrying either the p426GalL-E4orf4 plasmid or the p426GalL vector were grown to midlog phase in glucose, washed once, and resuspended in galactose. Samples were removed every 90 min after induction by galactose, and cellular DNA content was measured by FACS® analysis. (B) Cells expressing a GFP–Tub1 fusion, and carrying either the p426GalL-E4orf4 plasmid or the p426GalL vector, were induced with galactose for 8 h. Cells were harvested, fixed with 4% paraformaldehyde, stained with DAPI, and visualized by light microscopy (left), by fluorescence in the DAPI channel (middle), or in the FITC channel to detect GFP–tubulin fluorescence (right) at a 1,000× magnification.
Figure 5.Functional interaction of E4orf4 with Mih1. (A) To compare E4orf4 expression levels from the pDAD and p426-GalL vectors, cells were induced with galactose for 3 h, and E4orf4 levels were determined by Western blot. (B) Wild-type or mih1Δ cells carrying the indicated plasmids were grown on galactose plates for 2 d. (C) KY630 (MIH1) or KY631 (mih1Δ) cells carrying a CLB2-3xHA construct integrated at CLB2 and transformed with either vector or p426GalL-E4orf4 were induced for 6 h with galactose. Clb2-associated kinase activity in the extracts was determined using Histone H1 as substrate. The amount of Histone H1 phosphorylation was measured with a phosphorimager. (D) Clb2-3xHA levels in the extracts described in C were determined by Western blotting. C, a no tag control; G1, an extract of CLB2-3xHA-expressing mutant cells arrested at restrictive temperature in G1. (E) MIH1 and mih1Δ cells were transformed with the indicated plasmids, and serial dilutions were plated dropwise on galactose plates.
Figure 6.E4orf4-expressing cells are supersensitive to benomyl. Cells expressing low levels (pDAD-E4orf4) or high levels (p426-GalL-E4orf4) of E4orf4 or the E4orf4A3 mutant were grown in liquid medium containing glucose, serially diluted, and grown on galactose-containing plates, with or without 15 μg/ml benomyl, for 2 d.
Figure 7.Effect of E4orf4 on degradation of APC/C substrates. (A) Degradation of Ase1-3xMyc in cells expressing E4orf4 from the p426-GalL-E4orf4 plasmid was measured by pulse–chase analysis. Cells arrested in G1 with α-factor were induced for 6 h with galactose. FACS® analysis of the cell population at the time of the chase indicates that the G1 arrest was maintained throughout the induction. The graph shows the result of the quantitation of the Ase1 band by phosphorimager. (B) Accumulation of Pds1-3xMyc in control versus p426-GalL-E4orf4–containing cells was measured by Western blotting after 6 h of galactose induction. Cells arrested by nocodazole (NOC) served as control.
Figure 8.E4orf4 targets PP2A to the APC/C. (A) Cells expressing wild-type E4orf4 or the A3 mutant from the galactose-inducible promoter, and HA-tagged Cdc16, were induced with galactose for 5 h. Proteins were immunoprecipitated with antibodies to E4orf4, and the presence of HA-Cdc16, Tpd3, and E4orf4 in the immune complexes was detected by a Western blot. (B) W303 and tpd3Δ cells expressing wild-type E4orf4 and the HA-tagged Cdc16 were induced as in A. Proteins were immunoprecipitated with antibodies to Tpd3, and the presence of HA-Cdc16 and Tpd3 in the immune complexes was detected by a Western blot. (C) CDC20 and cdc20-1 cells were transformed with pADH-CDC55 or a vector plasmid and plated on SC-LEU to select for transformants.
Figure 9.Induction of G 293 cells expressing E4orf4 from a tetracycline- inducible promoter (E4orf4-positive cell line) and control cells (E4orf4-negative cell line) were induced with increasing concentrations of doxycycline. FACS® analysis was performed for each point.
Figure 10.A schematic model for the mechanism of E4orf4 interference with cell cycle regulation. APC/C activity in E4orf4- expressing cells results from the net effect of activation by Cdc28 and inactivation by E4orf4/PP2A (see text for details).
Yeast strains
| Strain | Genotype | Reference or source |
|---|---|---|
| W303-1A |
| R. Rothstein |
| 10131-7C |
| G. Fink |
| H314 | α |
|
| H339 | ura3-1 leu2-3,112 trp1-1 ade2-1 pph3::LEU2 |
|
| H341 |
|
|
| rts1-null | α |
|
| rts1-null,cdc55-null | α |
|
|
|
|
|
| K1989 |
| K. Nasmyth |
| K1993 |
| K. Nasmyth |
| A364 |
| A. Amon |
| A368 |
| A. Amon |
| A460 |
| A. Amon |
| A544 |
| A. Amon |
| A698 |
| A. Amon |
| W321 |
|
|
| MTY670 |
| M. Tyers |
| MTY740 |
| M. Tyers |
| PS694 | α | P. Sorger |
| K7375 |
|
|
| KH123 |
|
|
| KH141 |
|
|
| KH125 |
|
|
| KH127 |
|
|
| KH128 |
|
|
| ADR2032 |
|
|
| KY520 | α | This work |
| KY547 |
| This work |
| KY596 |
| This work |
| KY600 |
| This work |
| KY620 | α | This work |
| KY630 | W303 | This work |
| KY631 | KY620 | This work |
| KY679 |
| This work |
Columbia University, New York, NY.
S. Luneberg Institute, Toronto, Ontario, Canada.
Massachusetts Institute of Technology, Cambridge, MA.